Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Authors: Marlijn Hoeks, Tim Bagguley, Corine van Marrewijk, Alex Smith, David Bowen, Dominic Culligan, Seye Kolade, Argiris Symeonidis, Hege Garelius, Michail Spanoudakis, Saskia Langemeijer, Rian Roelofs, Erwin Wiegerinck, Aurelia Tatic, Sally Killick, Panagiotis Panagiotidis, Oana Stanca, Eva Hellström-Lindberg, Jaroslav Cermak, Melanie van der Klauw, Hanneke Wouters, Marian van Kraaij, Nicole Blijlevens, Dorine W. Swinkels, Theo de Witte, R. Stauder, A. Walder, M. Pfeilstöcker, A. Schoenmetzler-Makrai, S. Burgstaller, J. Thaler, I. Mandac Rogulj, M. Krejci, J. Voglova, P. Rohon, A. Jonasova, J. Cermak, D. Mikulenkova, I. Hochova, P. D. Jensen, M. S. Holm, L. Kjeldsen, I. H. Dufva, H. Vestergaard, D. Re, B. Slama, P. Fenaux, B. Choufi, S. Cheze, D. Klepping, B. Salles, B. de Renzis, L. Willems, D. De Prost, J. Gutnecht, S. Courby, V. Siguret, G. Tertian, L. Pascal, M. Chaury, E. Wattel, A. Guerci, L. Legros, P. Fenaux, R. Itzykson, L. Ades, F. Isnard, L. Sanhes, R. Benramdane, A. Stamatoullas, S. Amé, O. Beyne-Rauzy, E. Gyan, U. Platzbecker, C. Badrakan, U. Germing, M. Lübbert, R. Schlenk, I. Kotsianidis, C. Tsatalas, V. Pappa, A. Galanopoulos, E. Michali, P. Panagiotidis, N. Viniou, A. Katsigiannis, P. Roussou, E. Terpos, A. Kostourou, Z. Kartasis, A. Pouli, K. Palla, V. Briasoulis, E. Hatzimichael, G. Vassilopoulos, A. Symeonidis, A. Kourakli, P. Zikos, A. Anagnostopoulos, M. Kotsopoulou, K. Megalakaki, M. Protopapa, E. Vlachaki, P. Konstantinidou, G. Stemer, A. Nemetz, U. Gotwin, O. Cohen, M. Koren, E. Levy, U. Greenbaum, S. Gino-Moor, M. Price, Y. Ofran, A. Winder, N. Goldshmidt, S. Elias, R. Sabag, I. Hellman, M. Ellis, A. Braester, H. Rosenbaum, S. Berdichevsky, G. Itzhaki, O. Wolaj, S. Yeganeh, O. Katz, K. Filanovsky, N. Dali, M. Mittelman, L. Malcovati, L. Fianchi, A. vd Loosdrecht, V. Matthijssen, A. Herbers, H. Pruijt, N. Aboosy, F. de Vries, G. Velders, E. Jacobs, S. Langemeijer, M. MacKenzie, C. Lensen, P. Kuijper, K. Madry, M. Camara, A. Almeida, G. Vulkan, O. Stanca Ciocan, A. Tatic, A. Savic, C. Pedro, B. Xicoy, P. Leiva, J. Munoz, V. Betes, C. Benavente, M. Lozano, M. Martinez, P. Iniesta, T. Bernal, M. Diez Campelo, D. Tormo, R. Andreu Lapiedra, G. Sanz, E. Hesse Sundin, H. Garelius, C. Karlsson, P. Antunovic, A. Jönsson, L. Brandefors, L. Nilsson, P. Kozlowski, E. Hellstrom-Lindberg, M. Grövdal, K. Larsson, J. Wallvik, F. Lorenz, E. Ejerblad, D. Culligan, C. Craddock, S. Kolade, P. Cahalin, S. Killick, S. Ackroyd, C. Wong, A. Warren, M. Drummond, C. Hall, K. Rothwell, S. Green, S. Ali, D. Bowen, M. Karakantza, M. Dennis, G. Jones, J. Parker, A. Bowen, R. Radia, E. Das-Gupta, P. Vyas, E. Nga, D. Creagh, J. Ashcroft, J. Mills, L. Bond
Journal: Leukemia (2020)

Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS) [1]. Transfusion dependency in LRMDS patients is associated with inferior outcomes, mainly attributed to severe bone marrow failure [2]. However, iron toxicity, due to frequent RBCT or ineffective erythropoiesis, may be an additional negative prognostic factor [3,4,5,6]. Recently, much progress has been made in unraveling the iron metabolism. The peptide hormone hepcidin is the key regulator by inhibiting iron uptake through degradation of ferroportin, a cellular iron exporter [7]. Erythroferrone and GDF15, produced by erythroblasts, inhibit hepcidin production, which leads to increased uptake and cellular release of iron for the purpose of erythropoiesis [8]. The pathophysiology of iron metabolism in MDS is still not completely understood. Exceedingly high reactive oxygen species (ROS) levels are associated with iron toxicity, disease development, and progression in MDS patients [9,10,11,12]. Malondialdehyde (MDA), resulting from lipid peroxidation of polyunsaturated fatty acids, is a biomarker of oxidative stress [10, 12]. Currently, little is known about the prognostic impact of ROS in MDS patients. The aim of this study is twofold: (1) describe iron and oxidative stress parameters over time in LRMDS patients and (2) to assess their effect on overall and progression-free survival. The EUMDS registry prospectively collects observational data on newly diagnosed LRMDS patients from 148 centers in 16 countries in Europe and Israel as of January 2008. All patients provided informed consent. Clinical data were collected at baseline and at each six-monthly follow-up visit. Serum samples were collected prospectively at each visit from 256 patients included in six participating countries. Conventional iron parameters were measured with routine assays. We additionally analyzed hepcidin, growth differentiation factor 15 (GDF15), soluble transferrin receptor (sTfR), non-transferrin bound iron (NTBI), labile plasma iron (LPI), and MDA. Subjects were prospectively followed until death, loss to follow-up, or withdrawal of consent. All iron parameters were measured centrally at the department of Laboratory Medicine of the Radboudumc, Nijmegen, The Netherlands. Serum samples were collected just prior to transfusion in transfusion-dependent patients and stored at −80 °C. Details on the assays and reference ranges of hepcidin, GDF15, sTfR, NTBI, LPI, and MDA are provided in the supplement. The Spearman rank test was used to evaluate correlations between iron parameters. We stratified the results by transfusion dependency per visit and the presence of ring sideroblasts. When evaluating temporal changes in iron parameters, with linear quantile mixed models, we excluded patients from the timepoint they received iron chelation therapy. Overall survival (OS) was defined as the time from MDS diagnosis to death or, in case of progression-free survival, to date of progression or death; patients still alive at the end of follow-up were censored. Time-dependent Kaplan–Meier curves and cox proportional hazards models were used. In total, 256 consecutive patients, were included in this study. Over five six-monthly visits, 1040 samples were collected. Table 1 describes the patient characteristics. Most patients without ring sideroblasts were transfusion-independent at diagnosis (nonRS-TI; 55.9%), 18.8% with ring sideroblasts were transfusion-independent (RS-TI), 18.4% without ring sideroblasts were transfusion-dependent (nonRS-TD), and 7% with ring sideroblasts were transfusion-dependent patients (RS-TD). The median follow-up time was 6.6 years (95% CI 5.9–7.0). LPI was positively correlated with transferrin saturation (TSAT) (r = 0.15, p < 0.001, Fig. S1). LPI values increased exponentially at TSAT values above 80%. This effect was most pronounced in the transfusion-dependent groups, but also observed in the RS-TI group. MDA was weakly correlated with NTBI (r = 0.09, p = 0.069) and negatively correlated with hemoglobin level (r = −0.1, p = 0.033). GDF15 and hepcidin were negatively correlated in the RS-TI and nonRS-TD group and significantly negatively correlated in the RS-TD group (r = −0.34, p = 0.007, Fig. S2). Serum ferritin levels were elevated in all subgroups with a mean value of 858 µg/L at visit 5. The highest serum ferritin levels were observed in the RS-TD group (mean value at visit 5: 2092 µg/L, Table S1). Serum ferritin increased significantly per visit in the RS-TD group (beta 454.46 µg/L; 95% CI 334.65–574.27), but not in the other groups (Table S2). All subgroups, except for the nonRS-TI, had elevated TSAT levels. TSAT levels were most markedly increased in the RS-TD group with a mean TSAT of 88% at visit 5 (Table S1). In both transfusion-dependent groups the median increase per visit was significant (Table S2). LPI was elevated in the RS-TD group exclusively with a mean value of 0.59 µmol/L at visit 5 (Table S1). NTBI was elevated in all subgroups, with the highest values in the RS-TD group (Table S1). The increase in median NTBI level was significant in both transfusion-dependent groups (Table S2). Hepcidin levels were markedly elevated in the nonRS-TD group. Interestingly, hepcidin levels were lower in the RS-TD group, probably reflecting ineffective erythropoiesis, likewise supported by lower hepcidin/ferritin ratios in RS groups (Table S1). Median hepcidin levels increased over time in the transfusion-dependent subgroups only (Table S2). GDF15 levels, analyzed in the light of its potential role in hepcidin suppression, were increased in all subgroups (Table S1). The RS subgroups had higher GDF15 levels compared to the nonRS groups, reflecting increased erythropoiesis. Mean sTfR levels were within the reference range in all subgroups except for the RS-TI group, which showed elevated levels, reflecting...